NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.87 +4.25%

+$0.29 today

Market cap
$69.12M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.23M

Average 0.18M

NRXS EBITDA Margin

EBITDA as a percentage of revenue.

NeurAxis, Inc.AMEX: NRXS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -106.9%

EBITDA Margin was -106.9% in Q1 FY2026, up 146.5 pp from a year earlier. On a trailing-twelve-month basis it was -166.2%, up 110.2 pp year over year. Over 3 fiscal years it narrowed by 53.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -68.9% for the fiscal year ending Dec 2026, up from -214.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-106.9%+64.1 pp QoQ
Last fiscal yearDec 2025
-214.8%+79.4 pp YoY
LTMMar 2026
-166.2%+110.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+146.5 pp-19.8 pp-166.4 pp
1 year+79.4 pp+145.9 pp+66.4 pp
3 years-53.7 pp+222.1 pp+275.8 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-214.8%
Year-over-year change
+79.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NRXS compares with its peers on the latest reported figures

  • NRXS's LTM Mar 2026 EBITDA Margin of -166.2% is the highest of the 2 companies compared; the peer median is -3270.4%.
  • Its year-over-year change of +110.2 pp is the lowest of 2, against a peer median of +2655.9 pp.
NRXS Competitors Peer median
EBITDA Margin for NRXS and competitors
Company Period LTM level YoY 3-year change
NRXSNeurAxis, Inc.LTM Mar 2026-166.2% +110.2 pp-53.7 pp
RLYBRallybio CorporationLTM Mar 2026-3270.4% +2655.9 pp—
NERVMinerva Neurosciences, Inc.FY2025— ——
ENLVEnlivex Therapeutics Ltd.FY2025— ——
Peer median (excluding NRXS) -3270.4%+2655.9 pp—

Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M2.68M2.46M2.69M3.57M
Cost of Revenue467.66K297.06K303.35K362K562.92K
Gross Profit2.25M2.39M2.16M2.32M3.01M
Gross Margin82.8%88.9%87.7%86.5%84.2%
Research & Development203.41K225.61K169.32K206.11K493.61K
Selling, General & Admin5.02M5.53M8.65M9.27M10.34M
Operating Expenses5.22M5.76M8.82M9.48M10.84M
Depreciation & Amortization36.71K37.13K40.73K37.83K59.5K
EBITDA(2.95M)(4.33M)(9.23M)(7.9M)(7.67M)
EBITDA Margin-108.6%-161.1%-375.1%-294.2%-214.8%
Operating Income(2.97M)(3.37M)(6.66M)(7.16M)(7.83M)
Operating Margin-109.1%-125.6%-270.9%-266.5%-219.4%
Interest Income0(2.32M)(2.77K)00
Interest Expense36.93K417.6K5.36M300.72K73.97K
Other Income / Expenses(58K)(1.41M)(7.96M)(1.08M)29.35K
Income Before Tax(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Pre-Tax Margin-111.3%-178.0%-594.6%-306.8%-218.5%
Income Tax Expense00000
Net Income(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Net Margin-111.3%-178.0%-594.6%-306.8%-218.5%
EPS (Basic)(0.62)(0.57)(2.32)(1.22)(0.95)
EPS (Diluted)(0.62)(0.78)(2.32)(1.22)(0.95)
Weighted Avg Shares5.38M8.41M6.3M6.92M9.08M
Weighted Avg Shares (Diluted)5.38M8.41M6.3M6.92M9.08M

NeurAxis, Inc.

AMEX:NRXS

Intrinsic Alpha fair value

Locked

Current Price

$4.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.